Selina McKee | PharmaTimes

Blood test can detect more than 50 types of cancer

Selina McKee — Fri, 25 Jun 2021 11:26:00 +0000

Findings of the latest study assessing the test back its use as a screening tool, researchers say

Sanofi, Regeneron’s Libtayo cleared for basal cell carcinoma

Selina McKee — Fri, 25 Jun 2021 10:34:00 +0000

Libtayo is the first immunotherapy indicated for patients with advanced basal cell carcinoma

Patient Partnership Index 2021 – results announced!

Selina McKee — Thu, 10 Jun 2021 12:04:00 +0000

Three Gold Standards awarded for partnership work in patient advocacy and communications

£3m worth of illegally sold meds and devices seized in UK

Selina McKee — Wed, 09 Jun 2021 12:10:00 +0000

Under Operation Pangea, officers were also able to shut down or block 113,000 illegally operating websites

Amicus’ Pompe disease therapy joins early access scheme

Selina McKee — Wed, 09 Jun 2021 12:00:00 +0000

The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease

No survival benefit from aspirin in COVID-19 patients

Selina McKee — Wed, 09 Jun 2021 11:44:00 +0000

The NIHR-supported RECOVERY trial found that the anti-inflammatory drug does not improve survival for hospitalised patients with COVID-19

Gov’t announces delay to GP data extraction scheme

Selina McKee — Wed, 09 Jun 2021 11:42:00 +0000

The programme will now roll out early September to ensure patients have more time to consider whether to opt out of sharing their data

Novartis reports ‘clinically relevant’ survival data for Lutathera

Selina McKee — Fri, 04 Jun 2021 08:48:00 +0000

The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours

NICE turns down GSK’s IV Benlysta for systemic lupus

Selina McKee — Fri, 04 Jun 2021 08:28:00 +0000

The cost watchdog said uncertain trial evidence and cost-effectiveness estimates are behind the preliminary decision

Lynparza shows promise in preventing cancer recurrence

Selina McKee — Fri, 04 Jun 2021 08:05:00 +0000

Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting